[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,271
Citations 0
Comment & Response
January 20, 2015

Long-Acting β-Agonists With vs Without Inhaled Corticosteroids for COPD

Author Affiliations
  • 1Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada
  • 2Center for Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec, Canada
JAMA. 2015;313(3):305. doi:10.1001/jama.2014.16470

To the Editor In their observational study assessing the long-term outcomes associated with use of long-acting β-agonists (LABAs) in combination with inhaled corticosteroids (ICSs) in chronic obstructive pulmonary disease (COPD), Dr Gershon and colleagues1 reported that ICS use was not associated with pneumonia risk. This finding contradicts large randomized trials and observational studies, which have reported an increased risk of pneumonia with ICS use, particularly fluticasone.25

First Page Preview View Large
First page PDF preview
First page PDF preview
×